{"disease":{"id":"diffuse-large-cell-lymphoma-relapsed-refractory","name":"diffuse large cell lymphoma relapsed refractory"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03886831","title":"A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT07159906","title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":62,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT03422523","title":"Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":53,"lead_sponsor_name":"University Hospital Southampton NHS Foundation Trust","has_results":false},{"nct_id":"NCT04659434","title":"Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":51,"lead_sponsor_name":"Qian Wenbin","has_results":false},{"nct_id":"NCT04572763","title":"Copanlisib Plus Venetoclax in R/R DLBCL","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03719989","title":"Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":27,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06651853","title":"Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT01555541","title":"Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"C. Babis Andreadis","has_results":true},{"nct_id":"NCT07198230","title":"Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Ting YANG","has_results":false},{"nct_id":"NCT03153462","title":"Axicabtagene Ciloleucel Expanded Access Study","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}